Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus

References

• Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA298(7), 765–775 (2007).
   PubMed Web of Science ®Google Scholar
• González EL, Johansson S, Wallander MA, Rodríguez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996–2005. J. Epidemiol. Community Health63(4), 332–336 (2009).
   PubMed Web of Science ®Google Scholar
• Amin AP, Marso SP. Acute coronary syndrome in the patient with diabetes: is the management different?. Curr. Cardiol. Rep.12(4), 321–329 (2010).
   PubMedGoogle Scholar
• Bagust A, Hopkinson PK, Maslove L, Downs KE, Harrison DJ. Future prevalence and economic burden of Type 2 diabetes in the United States to 2050. Diabetes50, A205 838 (2001).
   Google Scholar
• Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med.339(4), 229–234 (1998).
   PubMed Web of Science ®Google Scholar
• Kuchulakanti PK, Chu WW, Torguson R et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation113(8), 1108–1113 (2006).
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA293(17), 2126–2130 (2005).
   PubMed Web of Science ®Google Scholar
• Urban P, Gershlick AH, Guagliumi G et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation113(11), 1434–1441 (2006).
   PubMed Web of Science ®Google Scholar
• Machecourt J, Danchin N, Lablanche JM et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J. Am. Coll. Cardiol.50(6), 501–508 (2007).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – Thrombolysis in Myocardial Infarction 38. Circulation118(16), 1626–1636 (2008).
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Angiolillo DJ. Diabetes and anti-platelet therapy in acute coronary syndrome. Circulation123(7), 798–813 (2011).
   PubMed Web of Science ®Google Scholar
• Ueno M, Ferreiro JL, Tomasello SD et al. Functional profile of the platelet P2Y12 receptor signalling pathway in patients with Type 2 diabetes mellitus and coronary artery disease. Thromb. Haemost.105(4), 105(4), 730–732 (2011).
   Google Scholar
• Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutr. Metab. Cardiovasc. Dis.19(6), 440–449 (2009).
   PubMed Web of Science ®Google Scholar
• Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation104(23), 2767–2771 (2001).
   PubMed Web of Science ®Google Scholar
• Feit F, Manoukian SV, Ebrahimi R et al. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J. Am. Coll. Cardiol.51(17), 1645–1652 (2008).
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists’ Collaboration Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ308(6921), 81–106 (1994).
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ324(7329), 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• Watala C, Pluta J, Golanski J et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J. Mol. Med.83(2), 148–158 (2005).
   PubMed Web of Science ®Google Scholar
• Davì G, Catalano I, Averna M et al. Thromboxane biosynthesis and platelet function in Type II diabetes mellitus. N. Engl. J. Med.322(25), 1769–1774 (1990).
   PubMed Web of Science ®Google Scholar
• Watala C, Golanski J, Pluta J et al. Reduced sensitivity of platelets from Type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb. Res.113(2), 101–113 (2004).
   PubMed Web of Science ®Google Scholar
• Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood61(6), 1081–1085 (1983).
   PubMed Web of Science ®Google Scholar
• Riondino S, Trifirò E, Principessa L et al. Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production. Thromb. Res.122(3), 359–365 (2008).
   PubMed Web of Science ®Google Scholar
• Feletou M, Cohen RA, Vanhoutte PM, Verbeuren TJ. TP receptors and oxidative stress: hand in hand from endothelial dysfunction to atherosclerosis. In: Advances in Pharmacology (Volume 60). Vanhoutte PM (Ed.). Academic Press, MA, USA, 85–106 (2010).
   Google Scholar
• Santilli F, Mucci L, Davì G. TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. Intern. Emerg. Med.6(3), 203–212 (2010).
   PubMedGoogle Scholar
• DiChiara J, Bliden KP, Tantry US et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes56(5), 3014–3019 (2007).
   PubMed Web of Science ®Google Scholar
• Capodanno D, Patel A, Dharmashankar K et al. Pharmacodynamic effects of different aspirin dosing regimens in Type 2 diabetes mellitus patients with coronary artery disease. Circ. Cardiovasc. Interv.4(2), 180–187 (2011).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345(7), 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes54(8), 2430–2435 (2005).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Ramírez C et al. Insulin therapy is associated with platelet dysfunction in patients with Type 2 diabetes mellitus on dual oral antiplatelet treatment. J. Am. Coll. Cardiol.48(2), 298–304 (2006).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Capodanno D et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J. Am. Coll. Cardiol.55(11), 1139–1146 (2010).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Shoemaker SB, Desai B et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation115(6), 708–716 (2007).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Costa MA, Shoemaker SB et al. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am. J. Cardiol.101(4), 440–445 (2008).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Tanguay JF, Eikelboom JW et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomized factorial trial. Lancet376(9748), 1233–1243 (2010).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capranzano P, Goto S et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur. Heart J.29(18), 2202–2211 (2008).
   PubMed Web of Science ®Google Scholar
• Agewall S, Badimon L, Drouet L et al. Oral antiplatelet agents in ACS: from pharmacology to clinical differences Fundam. Clin. Pharmacol. DOI: 10.1111/j.1472-8206.2010.00890 (2010) (Epub ahead of print).
   Google Scholar
• Norgard NB, Abu-Fadel M. Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc. Health Risk Manag.5, 873–882 (2009).
   PubMedGoogle Scholar
• Wilson W, Gurvitch R, Ajani AE. Prasugrel: a novel platelet ADP P2Y receptor antagonist. Cardiovasc. Ther.27(3), 194–198 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Badimon J, Saucedo JF et al. A pharmacodynamic comparison of prasugrel versus high dose clopidogrel in patients with Type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In Diabetes Mellitus (OPTIMUS)-3 trial. Eur. Heart J.32(7), 838–846 (2011).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.357(20), 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Murphy SA, Antman EM, Wiviott SD et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur. Heart J.29(20), 2473–2479 (2008).
   PubMed Web of Science ®Google Scholar
• Siddique A, Butt M, Shantsila E, Lip GYH. New antiplatelet drugs: beyond aspirin and clopidogrel. Int. J. Clin. Pract.63(5), 776–789 (2009).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation120(25), 2577–2585 (2009).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.361(11), 1045–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Harrington RA, James S et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. Lancet375, 283–293 (2010).
   PubMed Web of Science ®Google Scholar
• James S, Angiolillo DJ, Cornel JH et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Eur. Heart J.31, 3006–3016 (2010).
   PubMed Web of Science ®Google Scholar
• Wright RS, Anderson JL, Adams CD et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline). J. Am. Coll. Cardiol.57(19), e215–e367 (2011).
   PubMedGoogle Scholar
• Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction. Circulation116(7), e148–e304 (2007).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am. J. Cardiol.103(Suppl. 3), 27A–34A (2009).
   PubMed Web of Science ®Google Scholar
• Michelson AD, Cattaneo M, Eikelboom JW et al. Platelet physiology subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis; working group on aspirin resistance. aspirin resistance: position paper of the working group on aspirin resistance. J. Thromb. Haemost.3(6), 1309–1311 (2005).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol.49(14), 1505–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation115(25), 3156–3164 (2007).
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Furman MI, Linden MD et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation113(25), 2888–2896 (2006).
   PubMed Web of Science ®Google Scholar